01 1Hovione FarmaCiencia SA
01 1Viseltinib
01 1Portugal
NDC Package Code : 50909-1707
Start Marketing Date : 2025-02-14
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
87
PharmaCompass offers a list of Vimseltinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vimseltinib manufacturer or Vimseltinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vimseltinib manufacturer or Vimseltinib supplier.
PharmaCompass also assists you with knowing the Vimseltinib API Price utilized in the formulation of products. Vimseltinib API Price is not always fixed or binding as the Vimseltinib Price is obtained through a variety of data sources. The Vimseltinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vimseltinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vimseltinib, including repackagers and relabelers. The FDA regulates Vimseltinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vimseltinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vimseltinib supplier is an individual or a company that provides Vimseltinib active pharmaceutical ingredient (API) or Vimseltinib finished formulations upon request. The Vimseltinib suppliers may include Vimseltinib API manufacturers, exporters, distributors and traders.
click here to find a list of Vimseltinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vimseltinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vimseltinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vimseltinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vimseltinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vimseltinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vimseltinib suppliers with NDC on PharmaCompass.
